e-learning
resources
Copenhagen 2005
Sunday 18.09.2005
Therapeutic options for COPD: present and future
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cigarette smoke-induced IL-8 production by human monocyte-derived macrophages: synergistic inhibition by fluticasone and salmeterol
H. Sarir, E. Mortaz, F. Nijkamp, G. Folkerts (Utrecht, Netherlands)
Source:
Annual Congress 2005 - Therapeutic options for COPD: present and future
Session:
Therapeutic options for COPD: present and future
Session type:
Oral Presentation
Number:
216
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Sarir, E. Mortaz, F. Nijkamp, G. Folkerts (Utrecht, Netherlands). Cigarette smoke-induced IL-8 production by human monocyte-derived macrophages: synergistic inhibition by fluticasone and salmeterol. Eur Respir J 2005; 26: Suppl. 49, 216
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Synergistic anti-inflammatory effects of salmeterol and fluticasone on the release of IL-8 and MCP-1 by human bronchial epithelial cells
Source: Eur Respir J 2003; 22: Suppl. 45, 39s
Year: 2003
Overexpression of CBP augments cigarette smoke-induced pro-inflammatory cytokine release in macrophages
Source: Eur Respir J 2005; 26: Suppl. 49, 105s
Year: 2005
Effects of formoterol and salmeterol on the production of Th1- and Th2-related chemokines by monocytes and bronchial epithelial cells
Source: Eur Respir J 2008; 31: 1313-1321
Year: 2008
Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages
Source: Eur Respir J 2010; 36: 178-186
Year: 2010
Cigarette smoke markedly inhibits the LPS-induced production of interleukin-8 in bronchial epithelial cells and consequent neutrophil migration in vitro
Source: Eur Respir J 2004; 24: Suppl. 48, 100s
Year: 2004
Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells
Source: Eur Respir J 2001; 17: 1070-1077
Year: 2001
Induction of pro-inflammatory mediator release by cigarette smoke condensate: differential effects on alveolar epithelial cells and macrophages
Source: Eur Respir J 2003; 22: Suppl. 45, 81s
Year: 2003
Cigarette smoke induces the release of CXCL-8 from human bronchial epithelial cells via TLRs and the induction of inflammasome
Source: Annual Congress 2011 - Epithelial cell biology
Year: 2011
Fluticasone increases in vitro efferocytosis by human alveolar macrophages
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
LATE-BREAKING ABSTRACT: Roflumilast and its active metabolite inhibit LPS-induced cytokines production from human parenchymal and bronchial explants: interaction with formoterol
Source: Annual Congress 2009 - Airway cell biology
Year: 2009
TRPA1 mediates cigarette smoke-induced TNFa secretion in macrophages
Source: Virtual Congress 2021 – Environmental and lifestyle impacts on chronic lung disease
Year: 2021
The inhibitory effect of formoterol and salmeterol on the IP-10 (CXCL10) in bronchial epithelial cells
Source: Annual Congress 2009 - Models of chronic airways disease and therapy
Year: 2009
Inhibition of LPS-induced cytokine/chemokine production from human lung macrophages by roflumilast is enabled by autocrine PGE
2
Source: Annual Congress 2010 - Macrophages: cell biology and disease-specific characteristics
Year: 2010
Cigarette smoke can increase the neutrophil recruitment in the airways of COPD patients by increasing PGE2 release in alveolar macrophages (AM)
Source: Eur Respir J 2003; 22: Suppl. 45, 85s
Year: 2003
Suppressive effects of formoterol and salmeterol on eotaxin-1 in bronchial epithelial cells
Source: Annual Congress 2008 - Novel therapeutic approaches and immunological mechanisms in airway cell pathobiology
Year: 2008
Combination of budesonide and formoterol is more effective in inhibiting GM-CSF production by bronchial epithelial cells than either drug alone
Source: Eur Respir J 2003; 22: Suppl. 45, 457s
Year: 2003
Synergistic inhibition of oxidative burst in human eosinophils by combination treatment with formoterol and budesonide
Source: Eur Respir J 2001; 18: Suppl. 33, 48s
Year: 2001
Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo
Source: Eur Respir J 2003; 21: 994-999
Year: 2003
Antiinflammatory effects of formoterol in macrophages as a model for alveolar macrophages in COPD
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II
Year: 2008
Formoterol and salmeterol enhance cytokine release in primary bronchial epithelial cells
Source: Eur Respir J 2004; 24: Suppl. 48, 101s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept